New generic Multiple Sclerosis treatment
option, PrGlatiramer Acetate Injection 20 mg/mL for
once-daily injection, available for one of the largest MS
populations in the world
ETOBICOKE, ON, April 15,
2024 /CNW/ -- Viatris Inc. (NASDAQ: VTRS), a
global healthcare company, today announced the launch in
Canada of PrGlatiramer
Acetate Injection 20 mg/mL for once-daily injection, the first
generic bioequivalent version of Teva's Copaxone® 20
mg/mL, indicated for the treatment of patients with
Relapsing-Remitting Multiple Sclerosis (RMMS), a chronic
inflammatory disease of the central nervous system.
Viatris Canada's Country Manager Jeffrey
Long commented, "The launch of Glatiramer Acetate Injection
20 mg/mL, the first bioequivalent generic for Copaxone®
20 mg/mL, marks another significant milestone for Viatris Canada,
reinforcing our proven capabilities in bringing complex and
difficult-to-manufacture products to market, and furthering our
commitment to providing access to high quality medicines. MS
Canada estimates 90,000 Canadians
are living with Multiple Sclerosis—one of the highest rates of MS
in the world.i Because of this high prevalence, and
because MS affects each person differently, there is a need for a
range of medicines to help manage the symptoms of the disease and
other medical conditions that are commonly associated with MS."
Glatiramer Acetate Injection 20 mg/mL for once daily injection
was approved as a therapeutic equivalent to Copaxone® 20
mg/mL. Viatris generated bioequivalency and characterization data
on this product, formulated to have the same dosage form, route of
administration and strength as the branded counterpart. Glatiramer
Acetate Injection 20 mg/mL is available by prescription
only.ii
A comprehensive patient support program, VIATRIS ADVOCATE™,
offers services for patients including reimbursement navigation,
financial assistance for eligible patients, injection training and
on-going support from MS-experienced nurses.
For more information, please consult the Glatiramer Acetate
Product Monograph at: https://pdf.hres.ca/dpd_pm/00072479.PDF
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare
company uniquely positioned to bridge the traditional divide
between generics and brands, combining the best of both to more
holistically address healthcare needs globally. With a mission to
empower people worldwide to live healthier at every stage of life,
we provide access at scale, currently supplying high-quality
medicines to approximately 1 billion patients around the world
annually and touching all of life's moments, from birth to the end
of life, acute conditions to chronic diseases. With our
exceptionally extensive and diverse portfolio of medicines, a
one-of-a-kind global supply chain designed to reach more people
when and where they need them, and the scientific expertise to
address some of the world's most enduring health challenges, access
takes on deep meaning at Viatris. We are headquartered in the U.S.,
with global centers in Pittsburgh,
Shanghai and Hyderabad,
India. Learn more
at viatris.com and investor.viatris.com, and
connect with us on LinkedIn, Instagram,
YouTube and X (formerly Twitter).
|
|
|
|
|
i https://mscanada.ca/about-ms#:~:text=Canada%20has%20one%20of%20the,are%20diagnosed%20with%20MS%20everyday
|
ii
https://pdf.hres.ca/dpd_pm/00072479.PDF
|
SOURCE Viatris Inc.